Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies

Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

Novartis AG, which brought the first approved chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) to market, now is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business